Effects of a Psychotherapy Intervention in Depressed Patients With Coronary Artery Disease (SPIRR-CAD)

August 26, 2016 updated by: Christoph Herrmann-Lingen, University of Göttingen

A Stepwise Psychotherapy Intervention for Reducing Risk in Coronary Artery Disease - a Randomised Controlled Trial (SPIRR-CAD)

In patients with coronary artery disease (CAD), depressive symptoms are frequent and highly relevant for quality of life, health behaviour, health care costs, and prognosis. The aim of the current study is to evaluate the effects of a psychotherapy intervention on symptoms of depression in patients with CAD. Therefore, depressed patients diagnosed with CAD will be randomised into a controlled intervention trial, comparing a stepwise psychotherapy intervention with usual cardiological care. The manualized psychotherapy intervention starts with three individual sessions offered on a weekly basis. Afterwards, symptoms of depression will be re-evaluated and, in case of persisting symptoms, patients receive an additional 25 sessions of psychodynamic group psychotherapy over a total period of one year. The psychodynamic approach was chosen in order to specifically take into account personality traits such as negative affectivity and social inhibition, the components of the Type D personality, which may explain why recent cognitive behavioural psychotherapy (CBT) trials produced only small effects in depressed CAD patients. The investigators expect that the intervention will reduce depressive symptoms as well as the prevalence of depressive disorders. It will also improve both behaviourally and physiologically mediated cardiovascular risk indicators, promote better quality of life, and reduce healthcare costs. Subgroup analyses will be performed in order to identify gender-specific treatment effects, effects on immunological stress reactivity, and genetic predictors of treatment success.

Study Overview

Study Type

Interventional

Enrollment (Actual)

570

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Berlin, Germany, D-12200
        • Berlin University Medical Center, Campus Benjamin Franklin, Dept. of Psychosomatics and Psychotherapy
      • Cologne, Germany, D-50931
        • University of Cologne, Dept. Psychosomatics and Psychotherapy
      • Dresden, Germany, D-01307
        • Technical University of Dresden, Dept. of Psychotherapy and Psychosomatics
      • Freiburg, Germany, D-79104
        • University Hospital of Freiburg, Dept. of Psychosomatic Medicine and Psychotherapy
      • Goettingen, Germany, D-37075
        • University of Goettingen, Dept. of Psychosomatic Medicine and Psychotherapy
      • Hannover, Germany, D-30625
        • Hannover Medical School, Dept. of Psychosomatics and Psychotherapy
      • Heidelberg, Germany, D-69120
        • University of Heidelberg, Dept. of General Internal and Psychosomatic Medicine
      • Mainz, Germany, D-55131
        • University Hospital of Mainz, Dept. of Psychosomatic Medicine and Psychotherapy
      • Muenchen, Germany, D- 81675
        • Technical University of Munich, Institute and Dept. of Psychosomatic Medicine, Psychotherapy and Medical Psychology
      • Nuremberg, Germany, D-90419
        • Nuremberg General Hospital, Department of Psychosomatic Medicine and Psychotherapy

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 75 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Patients with coronary artery disease
  • German speaking men and women
  • Recent coronary angiogram (<= 3 months old)
  • Depression score (HADS-D) >= 8
  • Written informed consent

Exclusion Criteria:

  • Severe heart failure
  • Other acutely life- threatening conditions
  • Severe chronic inflammatory disease
  • Current suicidal tendency
  • Severe depressive episode
  • Other severe mental illness.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: 1
Stepwise, manualized individual and group psychotherapy in addition to usual cardiological care.
Stepwise, manualized individual and group psychotherapy in addition to usual cardiological care.
Other Names:
  • Stepwise manualized psychotherapy
Usual cardiological care
Active Comparator: 2
Usual cardiological care including one information session.
Usual cardiological care
One information session about living with heart disease.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Changes from baseline to 18 months in depressive symptoms (HADS-D)
Time Frame: 18 months
18 months

Secondary Outcome Measures

Outcome Measure
Time Frame
Remission of depressive disorder (SCID) and the Type D pattern (DS-14), reduced severity of depressive symptoms (HAM-D)
Time Frame: 18 months
18 months
Health-related quality of life (SF36, EuroQuol-5D)
Time Frame: 18 months
18 months
cardiovascular risk profile
Time Frame: 18 months
18 months
neuroendocrine and immunological activation
Time Frame: 18 months
18 months
coagulation
Time Frame: 18 months
18 months
heart rate variability
Time Frame: 18 months
18 months
cardiac events
Time Frame: 18 months
18 months
health care utilisation and costs
Time Frame: 18 months
18 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Christoph Herrmann-Lingen, MD, University of Goettingen, Dept. of Psychosomatic Medicine and Psychotherapy
  • Principal Investigator: Christian Albus, MD, University of Cologne, Dept. of Psychosomatics and Psychotherapy

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

November 1, 2008

Primary Completion (Actual)

April 1, 2013

Study Completion (Actual)

April 1, 2013

Study Registration Dates

First Submitted

June 25, 2008

First Submitted That Met QC Criteria

June 26, 2008

First Posted (Estimate)

June 27, 2008

Study Record Updates

Last Update Posted (Estimate)

August 30, 2016

Last Update Submitted That Met QC Criteria

August 26, 2016

Last Verified

August 1, 2016

More Information

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Depression

Clinical Trials on Psychotherapy

3
Subscribe